Express Mail: EV 630723145 US

U.S. National Phase of PCT/US2004/027896

Attorney Docket: I-2003.009 US

Preliminary Amendment

**Amendments to the Claims:** 

1. (Currently amended): [[Live]] A live, attenuated bacterium of the genus Escherichia,

Yersinia or Salmonella, said bacterium not having a functional tRNA<sub>5</sub> leu, for use in a vaccine.

2. (Currently amended): [[Live]] The live, attenuated bacterium for use according to claim

1, said bacterium not having a functional tRNA<sub>5</sub> as a result of a mutation in the *leux* gene.

3. (Currently amended): [[Live]] The live, attenuated bacterium for use according to claim 1

[[or 2]], wherein said bacterium is selected from the group consisting of E. coli, S. enterica

serotype typhimurium, enteritidis, choleraesuis, dublin, typhi, gallinarum, abortusovi, abortus-

equi [[or]] and pullorum.

4. (Currently amended): [[Live]] The live, attenuated bacterium for use according to claim 2

1-3, characterised in that wherein the mutation comprises an insertion and/or a deletion.

5. (Currently amended): [[Live]] The live, attenuated bacterium for use according to clams

1-4, characterised in that claim 1, wherein said bacterium carries a heterologous gene.

(Currently amended): [[Live]] The live, attenuated bacterium for use according to claim 5

characterised in that the , wherein the heterologous gene is inserted in the leux gene.

7. (Currently amended): Live attenuated A vaccine for the protection of animals and

humans against infection with a pathogenic bacterium or the pathogenic effects thereof,

characterised in that said vaccine comprises a comprising the bacterium as defined in claims

1-6 of claim 1 and a pharmaceutically acceptable carrier.

Page 3 of 6

Express Mail: EV 630723145 US

U.S. National Phase of PCT/US2004/027896

Attorney Docket: I-2003.009 US

**Preliminary Amendment** 

8. (Currently amended): Live attenuated <u>The</u> vaccine according to claim 7, eharacterised in that it comprises comprising an adjuvant.

9. (Currently amended): Live attenuated <u>The</u> vaccine according to claim 7 or 8, characterised in that it is in a freeze-dried form.

Claims 10-11 (Canceled).

12. (New): A method for protecting a susceptible human or animal from infection with a pathogenic bacterium, comprising administering an effective amount of vaccine according to claim 7.